Pharma Marketing Network
MAY 15, 2025
In a world of podcasts , reels, and AI-written content, its fair to ask: are white papers still pulling their weight in pharma marketing? For teams navigating omnichannel campaigns, strict MLR approvals, and buyer fatigue, the answer isn’t just “yes”it’s if done right, they work better than ever. Once the domain of technical audiences and B2B legacy brands, white papers have evolved.
Hospital Pharmacy Europe
MAY 15, 2025
One in three pharmacists in Great Britain (34%) are now independent prescribers, according to recent data from the General Pharmaceutical Council (GPhC). As of 31 March 2025, some 21,804 pharmacists now have an independent prescriber annotation, representing33% of all registered pharmacists in Great Britain, the data shows. However, the number of independent prescribers varies across England, Wales and Scotland.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Checkup by Singlecare
MAY 15, 2025
Wegovy (semaglutide) is a once-weekly weight-loss medication that belongs to a class of drugs called GLP-1 agonists. It is FDA approved for weight management and to reduce the risk of stroke, heart attack , or other cardiovascular death in people who are overweight or have obesity. Wegovy is self-injected at home, so users must know how to properly store their single-dose injector pens before use.
Drug Topics
MAY 15, 2025
Investigators report that patients experience weight loss with a reduced weekly dosage of the glucagon-like peptide-1 (GLP-1).
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Fierce Healthcare
MAY 15, 2025
Iodine Software's pre-bill solution can identify an extra 25% revenue savings per month for health systems after a patient is discharged. The savings could help justify investment in other AI products.
STAT
MAY 15, 2025
For the first time, scientists say they have reached into the genome of a severely ill child and rewritten the unique misspelling in his DNA. The results, published in the New England Journal of Medicine on Thursday, are a landmark in the 50-year quest to read and repair the code of life. The boy, a now 9.5-month-old named KJ, was diagnosed days after birth with an ultra-rare disease that impairs his liver’s ability to process ammonia, which can build up and cause permanent brain da
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
MAY 15, 2025
The CMS, within the HHS, wants feedback on how it can develop better digital health tools for Medicare beneficiaries and drive adoption.
The FDA Law Blog
MAY 15, 2025
By John W.M. Claud & Deborah L. Livornese Dr. Marty Makary took the stage on Thursday at the Food and Drug Law Institutes Annual Conference , continuing the tradition of Commissioners speaking at this event, but with a tone and tempo distinctly his own. Now firmly in the chair after the agencys controversial RIFswhich he was quick to remind everyone he did not initiateCommissioner Makary said that the FDAs future depends on rebuilding its culture, empowering its staff, and applying his visi
STAT
MAY 15, 2025
Attacks on efforts to diversify the sciences. Research grant terminations. Fear among scientists to speak out against the government. Cuts to international aid. These were some of a long list of concerns shared by three research leaders as they discussed the state of U.S. science at STAT’s Breakthrough Summit West in San Francisco on Wednesday.
The Thyroid Pharmacist
MAY 15, 2025
If youre a woman, its likely that youve experienced a urinary tract infection (UTI) at some point in your life. Some of us might even experience them more frequently than wed like (if thats you keep reading!). Between 50 and 60 percent of women will experience at least one UTI in their lifetime, and the prevalence of UTIs increases as we age. [1] In fact, its the most common outpatient infection in the U.S.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharma Times
MAY 15, 2025
Aspire-FTD study aims to stop disease progression with one-time treatment
PharmExec
MAY 15, 2025
Welireg marks the first FDA-approved non-surgical treatment option for locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma in patients over 12 years of age.
Pharmaceutical Technology
MAY 15, 2025
From predictive analytics to robotic warehousing, automation is unlocking new efficiencies in pharma logistics.
STAT
MAY 15, 2025
Rise and shine, another busy day is on the way. We can tell because the official mascots got an early start chasing down cats, squirrels, and other creatures darting about the Pharmalot campus. And then there is the noisy parade of vehicles passing nearby on their way to who knows what? As for us, we are firing up the trusty coffee kettle to brew another cup of stimulation.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmaceutical Technology
MAY 15, 2025
The US Food and Drug Administration (FDA) has accepted BioCryst Pharmaceuticals new drug application (NDA) for Orladeyo.
The Checkup by Singlecare
MAY 15, 2025
Ivermectin is a generic prescription medication that is approved by the Food and Drug Administration ( FDA ) to treat certain parasitic infections , such as intestinal strongyloidiasis and onchocerciasis. Without insurance, the cost of ivermectin is $157 for 20, 3 mg tablets. While there arent any over-the-counter alternatives available for ivermectin , you can lower the price of an ivermectin prescription in many ways.
Pharmaceutical Technology
MAY 15, 2025
The FDA has approved MSDs Welireg for rare adrenal tumours, and AbbVies Emrelis for treating c-Met+ lung cancer patients.
STAT
MAY 15, 2025
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox on Tuesdays and Thursdays. Spare a thought for the House lawmakers and staff on two committees who suffered through markups that ran through the night.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
The FDA Law Blog
MAY 15, 2025
Hyman, Phelps & McNamara, P.C. is pleased to announce that Sophia Gaulkin will be presenting and speaking on an expert panel at Informa Connectsannual Life Sciences Pricing & Contracting USA Summit , which is being held virtually and in-person in Philadelphia on May 19-21. Ms. Gaulkins presentation, Product Price Increases: A SPTR Practical Walkthrough , will provide an interactive case study outlining the hypothetical enforcement, appeal, and settlement scenarios that may apply to quali
STAT
MAY 15, 2025
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. Summit Therapeutics’ China vs. U.S. data showdown Dare I call it the most important study readout coming this summer? I’m referring to the pending announcement of the first clinical data from Summit Therapeutics and its buzzy PD-1-VEGF antibody ivonescimab derived from lung cancer patients in the U.S. and othe
Fierce Healthcare
MAY 15, 2025
Datavant is making moves to be a bigger player in the real-world data space. The company announced Thursday that it plans to acquire real-world evidence company Aetion.
STAT
MAY 15, 2025
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here. Good morning! Despite believing that headlines on STAT stories are “terrible,” former FDA head Robert Califf said at yesterday’s Summit that we’re “providing a tremendous service right now to the country by really interrogating what’s been called radical transparency.
Pharmaceutical Technology
MAY 15, 2025
Kaerus Bioscience has received US Food and Drug Administrations (FDA) designations for KER-0193 to treat Fragile X syndrome (FXS).
pharmaphorum
MAY 15, 2025
HHS Secretary Robert F Kennedy Jr would not explicitly endorse measles vaccines at Congressional hearings, and deflected questions on department cuts.
STAT
MAY 15, 2025
I always knew Elizabeth Holmes would have a second act. But I’m shocked it’s starting while she’s still behind bars. Elizabeth is now serving an 11-year sentence for defrauding investors in Theranos and has been banned from participating in federal health programs. The company was built on her claim that, at 19 years old, she had invented a device capable of running hundreds of tests from just a single drop of blood.
pharmaphorum
MAY 15, 2025
Sanofi is the latest European pharma group to promise a big capital investment programme on manufacturing and R&D in the US
Fierce Healthcare
MAY 15, 2025
A policy and advocacy shop spawned out of various Robert F. Kennedy Jr.-aligned groups feels like it's winning the war against the scientific establishment and the media. Now, the group of allies is pressing the advantage.
pharmaphorum
MAY 15, 2025
AbbVie has claimed its first global regulatory approval, from the FDA, for its C-met-targeting lung cancer ADC Emrelis
Pharmaceutical Commerce
MAY 15, 2025
A qualitative study aimed to strengthen systematic repurposing efforts within rare disease nonprofit organizations, while also providing a framework for data-driven drug repurposing.
Pharmafile
MAY 15, 2025
Kaerus Bioscience announces that its lead candidate KER-0193 has been granted both Orphan Drug Designation (ODD) and Rare Pediatric Drug Designations (RPDD) for the treatment of Fragile X syndrome (FXS) by the US Food and Drugs Administration (FDA). Created by Medicxi, the global biopharma is focused on the development of therapeutics for rare genetic syndromes […] The post Kaerus Bioscience secures FDA approval for rare genetic disorder treatment appeared first on Pharmafile.
Fierce Healthcare
MAY 15, 2025
The major nonprofit system reported an $85 million adjusted operating loss during its third fiscal quarter, but said that strong volumes couldn't outpace expense growth and reimbursement challenges.
European Pharmaceutical Review
MAY 15, 2025
New Phase IIb trial data has shown promising potential for Takeda’s oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1). The findings, published in the New England Journal of Medicine , show that oveporexton (TAK-861) significantly improved disease severity, and enabled participants to attain levels of wakefulness of nearly normal ranges.
Pharmaceutical Technology
MAY 15, 2025
This marks AbbVies second major siRNA deal following its $1.4bn acquisition of Aliada Therapeutics in 2024.
Expert insights. Personalized for you.
Let's personalize your content